183 related articles for article (PubMed ID: 15695383)
1. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23.
Bachinski LL; Olufemi SE; Zhou X; Wu CC; Yip L; Shete S; Lozano G; Amos CI; Strong LC; Krahe R
Cancer Res; 2005 Jan; 65(2):427-31. PubMed ID: 15695383
[TBL] [Abstract][Full Text] [Related]
2. [Li-Fraumeni syndrome].
Tsunematsu Y
Nihon Rinsho; 2000 Jul; 58(7):1442-7. PubMed ID: 10921321
[TBL] [Abstract][Full Text] [Related]
3. Balanced t(11;15)(q23;q15) in a TP53+/+ breast cancer patient from a Li-Fraumeni syndrome family.
Sherif ZA; Danielsen M
Cancer Genet Cytogenet; 2006 Jul; 168(1):50-8. PubMed ID: 16772121
[TBL] [Abstract][Full Text] [Related]
4. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
Evans SC; Lozano G
Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
[TBL] [Abstract][Full Text] [Related]
5. [Li-Fraumeni syndrome: update, new data and guidelines for clinical management].
Frebourg T; Abel A; Bonaiti-Pellie C; Brugières L; Berthet P; Bressac-de Paillerets B; Chevrier A; Chompret A; Cohen-Haguenauer O; Delattre O; Feingold J; Feunteun J; Frappaz D; Fricker JP; Gesta P; Jonveaux P; Kalifa C; Lasset C; Leheup B; Limacher JM; Longy M; Nogues C; Oppenheim D; Sommelet D; Soubrier F; Stoll C; Stoppa-Lyonnet D; Tristant H
Bull Cancer; 2001 Jun; 88(6):581-7. PubMed ID: 11459705
[TBL] [Abstract][Full Text] [Related]
6. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.
Lee SB; Kim SH; Bell DW; Wahrer DC; Schiripo TA; Jorczak MM; Sgroi DC; Garber JE; Li FP; Nichols KE; Varley JM; Godwin AK; Shannon KM; Harlow E; Haber DA
Cancer Res; 2001 Nov; 61(22):8062-7. PubMed ID: 11719428
[TBL] [Abstract][Full Text] [Related]
7. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds.
Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K
Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families.
Bougeard G; Sesboüé R; Baert-Desurmont S; Vasseur S; Martin C; Tinat J; Brugières L; Chompret A; de Paillerets BB; Stoppa-Lyonnet D; Bonaïti-Pellié C; Frébourg T;
J Med Genet; 2008 Aug; 45(8):535-8. PubMed ID: 18511570
[TBL] [Abstract][Full Text] [Related]
9. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
[TBL] [Abstract][Full Text] [Related]
10. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
[TBL] [Abstract][Full Text] [Related]
11. Familial gastric cancer and Li-Fraumeni syndrome.
Corso G; Pedrazzani C; Marrelli D; Pinto E; Roviello F
Eur J Cancer Care (Engl); 2010 May; 19(3):377-81. PubMed ID: 19674071
[TBL] [Abstract][Full Text] [Related]
12. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
Varley JM; McGown G; Thorncroft M; Santibanez-Koref MF; Kelsey AM; Tricker KJ; Evans DG; Birch JM
Cancer Res; 1997 Aug; 57(15):3245-52. PubMed ID: 9242456
[TBL] [Abstract][Full Text] [Related]
13. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
Vahteristo P; Tamminen A; Karvinen P; Eerola H; Eklund C; Aaltonen LA; Blomqvist C; Aittomäki K; Nevanlinna H
Cancer Res; 2001 Aug; 61(15):5718-22. PubMed ID: 11479205
[TBL] [Abstract][Full Text] [Related]
14. Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene.
Bougeard G; Brugières L; Chompret A; Gesta P; Charbonnier F; Valent A; Martin C; Raux G; Feunteun J; Bressac-de Paillerets B; Frébourg T
Oncogene; 2003 Feb; 22(6):840-6. PubMed ID: 12584563
[TBL] [Abstract][Full Text] [Related]
15. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family.
Stolzenberg MC; Brugières L; Gardes M; Dessarps-Freichey F; Chompret A; Bressac B; Lenoir G; Bonaïti-Pellié C; Lemerle J; Feunteun J
Oncogene; 1994 Oct; 9(10):2799-804. PubMed ID: 8084585
[TBL] [Abstract][Full Text] [Related]
16. A germ line mutation in exon 5 of the p53 gene in an extended cancer family.
Law JC; Strong LC; Chidambaram A; Ferrell RE
Cancer Res; 1991 Dec; 51(23 Pt 1):6385-7. PubMed ID: 1933902
[TBL] [Abstract][Full Text] [Related]
17. [Li-Fraumeni syndrome].
Frebourg T
Bull Cancer; 1997 Jul; 84(7):735-40. PubMed ID: 9339200
[TBL] [Abstract][Full Text] [Related]
18. Cancer risks from germ line tumor suppressor gene mutations.
Frebourg T; Malkin D; Friend S
Princess Takamatsu Symp; 1991; 22():61-70. PubMed ID: 1844252
[TBL] [Abstract][Full Text] [Related]
19. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
20. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
